Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
Completed · Phase 4
Conditions studied: Kidney Transplant, Diabetes Mellitus, Type 2, Diabetic Nephropathy
In brief
Protocol Title: Randomized open label study comparing the metabolic control of first Kidney Transplant recipients with Type 2 Diabetes Mellitus (DM) receiving either Prograf or Neoral as part of a ATG induction, prednisone free and blood monitored Cellcept immunosuppressive regimen. PURPOSE This is a single center medical research study to analyze post-transplant kidney recipients with pre-existing type 2 diabetes managed according to the recommended American Diabetes Association (ADA) guidelines. Prograf (Tac) and Neoral (CSA) are the two main medications to prevent rejection after transplantation. However, they may contribute to poorer diabetes control. The purpose of the study is to compare the effects of Prograf and Neoral on the control of Diabetes after kidney transplantation. In addition, all participants in this study will receive Thymoglobulin (anti-lymphocyte globulin) at the time of transplantation instead of long term prednisone (steroids).
Key facts
- Study ID
- NCT00296296
- Run by
- Stanford University
- People needed
- 29
- Starts
- 2005-06-01
- Expected to finish
- 2014-10-01
- Last updated by the study team
- 2017-10-06
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Inclusion Criteria
- Patient is a recipient of a first cadaveric kidney, or a kidney living donor mismatched (at least one mismatch.)
- Patient is a minimum of 18 years of age at the time of transplant.
- Patient has type 2 non-insulin dependent diabetes.
- Patient or legal guardian has signed and dated an Ethics Committee-approved informed consent document and is willing and able to follow study procedures.
- If female and is childbearing potential, patient has a negative pregnancy test and utilizes adequate contraceptive methods.
You may not qualify if…
- Recipients of a transplant graft from a donor age 65 and older.
- Recipient of a multi-organ transplant.
- Patients who are being re-transplanted will not be eligible for study.
- Patients who have lost a previous graft to rejection less than one year from transplant.
- Patient has any form of substance abuse, psychiatric disorder, or a condition in the opinion of the investigator, may invalidate communication with the investigator.
- PRA > 30%
Where it is running
- Stanford university Hospital and Clinics — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.